News

The study dubbed APHINITY, compared Perjeta-based regimen with Herceptin and chemotherapy alone as an adjuvant therapy in 4,805 people with operable HER2-positive eBC. The Perjeta-based regimen is made up of

A search committee of the Board of Directors has been created and will begin conducting a thorough process to identify Mr. Hendrickson’s replacement. Mr. Hendrickson will remain with

The new cognitive solution will use real-world data and advanced analytical techniques to better understand the anticipated outcomes of several breast cancer treatments. Novartis expertise in breast cancer, along with IBM

Today’s decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for the treatment of patients with this common type of bladder cancer. “Bladder cancer has

Under the terms of the agreement, Eloxx will become a wholly owned subsidiary of Sevion. Upon completion of the transaction, Sevion will change its name to Eloxx Pharmaceuticals,

Janssen Research & Development announced that Zytiga plus prednisone, in combination with androgen deprivation therapy (ADT) has showed a significant improvement in overall survival (OS) and prolonged radiographic

Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus. With thousands dying from Lassa every year—and the potential

The product will be renamed OBI-3424 effective immediately. OBI-3424 is a first-in-class prodrug that selectively releases a potent DNA alkylating agent in the presence of the AKR1C3 enzyme.

The applications were submitted for a single-tablet, including two-drug regimen of dolutegravir and rilpivirine for maintenance treatment of HIV-1 infection. ViiV Healthcare’s Tivicay is a dolutegravir, while Janssen